Research programme: neutropenia therapy - LTT Bio-PharmaAlternative Names: SRG
Latest Information Update: 07 Oct 2015
At a glance
- Originator LTT Bio-Pharma
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neutropenia
Most Recent Events
- 10 May 2010 Early research in Neutropenia in Japan (unspecified route)